SLC16A1P1

Across TCGA pan-cancer cohorts, SLC16A1P1 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of SLC16A1P1’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where SLC16A1P1 RNA is repressed in tumor relative to normal tissue. In most cancer types SLC16A1P1 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

THCA and HNSC are the cancer types where SLC16A1P1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC16A1P1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	II,III,IV	−0.026	.030	2	view →
HNSC	Male	III,IV	+0.016	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 2 strongest of 2 lineages.

SLC16A1P1–THCA

Open the THCA breakdown →